UB Paderborn / Katalog / Suche / in CDI

1 – 10 von 10

Sortiert nach

The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma

Oncogene, 2020-02, Vol.39 (8), p.1652-1664

2020

Volltextzugriff (PDF)

Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses

The Journal of immunology (1950), 2017-06, Vol.198 (11), p.4205-4209

2017

Volltextzugriff (PDF)

1161 Development of TLR7- and STING-conjugatable agonists for immunostimulatory ADC-based cancer therapies

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1280-A1280

2023

Volltextzugriff (PDF)

Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer

Molecular therapy. Methods & clinical development, 2023-06, Vol.29, p.162-172

2023

Volltextzugriff (PDF)

Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine–Inosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes (STING)

Journal of medicinal chemistry, 2016-11, Vol.59 (22), p.10253-10267

2016

Volltextzugriff (PDF)

Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity

The Journal of immunology (1950), 2014-12, Vol.193 (12), p.5781-5785

2014

Volltextzugriff (PDF)

Molecular Signaling of Somatostatin Receptors

Annals of the New York Academy of Sciences, 2004-04, Vol.1014 (1), p.121-131

2004

Volltextzugriff (PDF)

Abstract B96: Non-viral gene therapy for pancreatic cancer, from preclinical models to phase II clinical trial

Cancer research (Chicago, Ill.), 2015-07, Vol.75 (13_Supplement), p.B96-B96

2015

Volltextzugriff (PDF)

Abstract 3532A: Development of gene therapy for pancreatic carcinoma: from experimental models to phase I clinical trial

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3532-3532A

2013

Volltextzugriff (PDF)

Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models

Cancer research (Chicago, Ill.), 2002-11, Vol.62 (21), p.6124-6131

2002

Volltextzugriff (PDF)

1 – 10 von 10

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(10)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(10)

Sprache

Englisch
(10)
Japanisch
(2)

Erscheinungsjahr

n.n

Kollektion

EZB Free E-Journals
(9)
MEDLINE
(6)
Single Journals
(6)
Journals@Ovid Complete
(2)
Wiley Online Library - AutoHoldings Journals
(1)
Wiley Online Library Full Collection 2018
(1)
Nexis Uni
(1)
BMJ Journals
(1)
Nature
(1)
Springer Journals
(1)
Ingenta Connect
(0)

6 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma

Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses

1161 Development of TLR7- and STING-conjugatable agonists for immunostimulatory ADC-based cancer therapies

Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer

Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine–Inosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes (STING)

Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity

Molecular Signaling of Somatostatin Receptors

Abstract B96: Non-viral gene therapy for pancreatic cancer, from preclinical models to phase II clinical trial

Abstract 3532A: Development of gene therapy for pancreatic carcinoma: from experimental models to phase I clinical trial

Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models

Aktive Filter

Suchergebnisse filtern